Clinical Trials Logo

Clinical Trial Summary

A prospective, longitudinal, cross-sectional, observational Study with a 8-week Follow-up to evaluate the renewal of corneal nerves structure and function in patients with Neurotrophic Keratopathy treated with recombinant human Nerve Growth Factor (rhNGF) eyedrops.


Clinical Trial Description

This Study shows that topical treatment with Recombinant Nerve Growth Factor (rhNGF) improved corneal sensitivity and increased sub-basal nerves density, promoting corneal healing of persistent epithelial defects and corneal ulcers in patients with stage 2 and 3 NK ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04293549
Study type Observational
Source G. d'Annunzio University
Contact
Status Completed
Phase
Start date March 1, 2018
Completion date November 30, 2018

See also
  Status Clinical Trial Phase
Terminated NCT02600429 - Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1 Phase 3
Recruiting NCT04604834 - Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy N/A
Not yet recruiting NCT06412718 - Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
Completed NCT04957758 - Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy Phase 2
Terminated NCT03084861 - A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy Phase 1/Phase 2
Active, not recruiting NCT06411145 - Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis Phase 4
Recruiting NCT05555589 - Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2 Phase 3
Not yet recruiting NCT06331910 - Efficacy and Safety of Topical Insulin for Neurotrophic Corneal Ulcers Phase 4